Abstract

Compounded Pain Formulations: What is the Evidence?

Author(s): Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso

Issue: Jul/Aug 2014 - Volume 18, Number 4

Page(s): 278-286

Download in electronic PDF format for $75
  • Compounded Pain Formulations: What is the Evidence? Page 1
  • Compounded Pain Formulations: What is the Evidence? Page 2
  • Compounded Pain Formulations: What is the Evidence? Page 3
  • Compounded Pain Formulations: What is the Evidence? Page 4
  • Compounded Pain Formulations: What is the Evidence? Page 5
  • Compounded Pain Formulations: What is the Evidence? Page 6
  • Compounded Pain Formulations: What is the Evidence? Page 7
  • Compounded Pain Formulations: What is the Evidence? Page 8
  • Compounded Pain Formulations: What is the Evidence? Page 9

Abstract

Pain syndromes are among the most widespread, costly, and debilitating of all neurological disorders. The number of patients living with chronic pain is expected to increase with the aging population and with the rise in obesity and diabetes across the nation. This type of pain is often insensitive to the traditional pain pharmacopeia or surgical intervention. Over the last 10 years the number of prescriptions that have been compounded by pharmacists has increased dramatically. There are a number of drugs in the area of pain management that have been formulated and compounded by pharmacists to treat conditions such as diabetic neuropathy, fibromyalgia, postherpetic neuralgia, joint pain, arthritis, and a variety of other conditions. A significant portion of these compounded analgesic preparations is made up of topical/transdermal dosage forms such as gels and creams. While the efficacy and doses of these drugs in systemic dosage forms have been widely established, little is known about the permeation and efficacy of these compounds from topical/transdermal gels. This review will provide an overview of chronic pain as a disease, the mechanisms of chronic pain, current treatment approaches to chronic pain, and a discussion of the drugs that are typically compounded into these topical formulations and studied in clinical trials.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2014
Pg. 278-286
Mar/Apr 2024
Pg. 100-109
May/Jun 2010
Pg. 182-192
May/Jun 2010
Pg. 200-203
Author(s): Bramwell Bethany L
Mar/Apr 2016
Pg. 107-113
Author(s): Rabi Joseph
Jul/Aug 2015
Pg. 295-300
Mar/Apr 2024
Pg. 111-116
Jan/Feb 2002
Pg. 4-6
Author(s): Jones Marty
May/Jun 2009
Pg. 182-190
May/Jun 2010
Pg. 204-206
Author(s): Williams KaCee D
Mar/Apr 2006
Pg. 159-160
Author(s): McNulty Jack P
May/Jun 2014
Pg. 182-188
Jan/Feb 2018
Pg. 19-24
May/Jun 2008
Pg. 182-190
Author(s): Vadaurri Vince
Nov/Dec 2023
Pg. 468-473
Nov/Dec 2008
Pg. 498-504
Jan/Feb 2000
Pg. 6-15
Author(s): Jones Marty
Mar/Apr 2016
Pg. 155-158
Nov/Dec 2016
Pg. 517-520
May/Jun 2016
Pg. 250-256
Author(s): Trimble John, Light Bob